Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
232.3(c) 237.27(c) 237.54(c) 226.92(c) 230.29(c) Last
2 874 193 2 221 295 3 137 154 3 275 733 2 872 028 Volume
-0.85% +2.14% +0.11% -4.47% +1.49% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 984 M - -
Net income 2021 -581 M - -
Net cash position 2021 714 M - -
P/E ratio 2021 -28,6x
Yield 2021 -
Sales 2022 5 493 M - -
Net income 2022 2 763 M - -
Net cash position 2022 2 524 M - -
P/E ratio 2022 7,13x
Yield 2022 -
Capitalization 17 153 M 17 153 M -
EV / Sales 2021 8,28x
EV / Sales 2022 2,66x
Nbr of Employees 792
Free-Float 98,7%
More Financials
Company
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline... 
More about the company
Ratings of Novavax, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about NOVAVAX, INC.
09/20NOVAVAX : to Participate in Fireside Chat at Devex @ UNGA 76
PR
09/20NOVAVAX : Statement on Proof of COVID-19 Vaccine Requirements for PREVENT-19 Clinical Tria..
AQ
09/20INSIDER SELL : Novavax
MT
09/20NOVAVAX : 15,000 Brits who took part in Novavax trials unable to prove Covid vaccine statu..
AQ
09/17NOVAVAX : StatementCOVID-19
PU
09/17Biocon unit plans 15% stake sale to Serum Institute for access to vaccines
RE
09/17NOVAVAX : Joins Oxford University's Study Comparing Mixed COVID-19 Vaccine Regimen in Adol..
MT
09/16UK Study to Mix Three COVID-19 Vaccine Doses in Adolescents
MT
09/16NOVAVAX : to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 V..
PR
09/15INDONESIA IN TALKS WITH WHO TO BECOM : minister
RE
09/13Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO
RE
09/13TAKEDA PHARMACEUTICAL : Novavax Statement on Takeda Agreement to Provide 150 Million Doses..
AQ
09/10NOVAVAX : expects to make available at least 2 bln COVID-19 vaccine doses in 2022
RE
09/10NOVAVAX : StatementCOVID-19
PU
09/09NOVAVAX INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
More news
News in other languages on NOVAVAX, INC.
09/21COVID : India riprenderà a esportare vaccini verso Paesi in via di sviluppo
09/17Novavax participe à une étude de l'Université d'Oxford comparant le schéma vaccinal mix..
09/13Takeda envisage la croissance de ses activités dans le domaine des vaccins grâce aux pr..
09/10Novavax prévoit de mettre à disposition au moins 2 milliards de doses de vaccin COVID-1..
09/09MODERNA : cherche à associer rappel anti-COVID et vaccin contre la grippe
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700024010 | MarketScreener
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 230,29 $
Average target price 264,20 $
Spread / Average Target 14,7%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.106.52%17 153
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021